Opana Addiction News
Table of Contents FDA Requests Removal of Opana ER for Risks Related to Abuse Abuse and Manipulation of Opana ER Resources and References: Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medicine, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal…
Details